Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002835 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy in Treating Patients With Lymphoma
A Phase 3 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 116
- Enrollment target
NCT00002835: Completed Phase 3 study, sponsored by M.D. Anderson Cancer Center.
NCT00002835 is a Phase 3 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 116 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002835, a Phase 3 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 116 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of two regimens of combination chemotherapy in treating patients who have intermediate-grade or immunoblastic lymphoma.
Interventions
- DRUG Carmustine
- BIOLOGICAL Recombinant Interferon Alfa
- BIOLOGICAL Filgrastim (G-CSF)
- BIOLOGICAL Bleomycin Sulfate (BLM)
- DRUG Cisplatin (CDDP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 1995-10-30 |
| Est. Completion | 2004-02-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002835
The ClinicalTrials.gov registry entry for NCT00002835 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carmustine is the first listed.
NCT00002835 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002835 about?
NCT00002835 is a clinical study titled "Combination Chemotherapy in Treating Patients With Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Randomized p...
What is the current status of trial NCT00002835?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 116 participants. The study started on 1995-10-30. Estimated completion is 2004-02-04.
What interventions are being tested in trial NCT00002835?
The interventions under investigation include: Carmustine (DRUG), Recombinant Interferon Alfa (BIOLOGICAL), Filgrastim (G-CSF) (BIOLOGICAL), Bleomycin Sulfate (BLM) (BIOLOGICAL), Cisplatin (CDDP) (DRUG).
Who is sponsoring clinical trial NCT00002835?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.